Pancreas · 2014 · 37 citations · 20 references
MedicineMolecular BiologyOncologyMolecular OncologyTranscriptional RegulationTumor ProgressionCancer Cell SignalingMolecular Tumor ProfilingOncogenic Signaling PathwaysPancreatic CancerSignal Transduction In CancerTumor Suppressor GenesApoptotic ResponseCancer Cell Line ModelsCancer Signaling PathwaysCell Growth RegulationInterferon Pathway GenesTumor Differentiation AssessmentTumor Size PrognosisTumor Suppressor Pathways
OBJECTIVE: Pancreatic cancer is one of the most malignant diseases worldwide. Interferon regulatory factor (IRF) 1 and IRF2 function as a tumor suppressor and oncoprotein, respectively, in several types of cancers. We investigated whether IRF1 and IRF2 are involved in the progression of pancreatic cancer. METHODS: We examined the expressions of IRF1 and IRF2 in pancreatic cancer specimens and analyzed the association with clinicopathologic features. We evaluated the biological effects of IRF1 and IRF2 using a pancreatic cancer cell line. RESULTS: The expression levels of IRF1 and IRF2 were decreased and increased, respectively, in the pancreatic cancer cells compared with those observed in the paired normal areas. A higher expression of IRF1 was associated with better features of tumor differentiation, infiltration depth, tumor size, and survival, whereas that of IRF2 was associated with a worse feature of tumor infiltration depth. Interferon regulatory factor 2-overexpressing PANC-1 cells exhibited an increase in cell growth, less apoptotic features, and chemoresistance to gemcitabine treatment. In contrast, IRF1-overexpressing cells exhibited the opposite characteristics. CONCLUSIONS: Interferon regulatory factors 1 and 2 may regulate the progression of pancreatic cancer by functioning as an antioncoprotein and oncoprotein, respectively. These molecules may serve as potential targets of therapy.
20
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.9K citations
Medicine, Oncology, Pharmacology +17
Anti-Oncogenic and Oncogenic Potentials of Interferon Regulatory Factors-1 and -2
Hisashi Harada, Motoo Kitagawa, Nobuyuki Tanaka et al. · Science · 1993 · 448 citations
Medicine, Cancer Biology, Oncology +16
The IRF family of transcription factors
Hideyuki Yanai, Hideo Negishi, Tadatsugu Taniguchi · OncoImmunology · 2012 · 264 citations · Full text
Life Sciences, Immunology, Oncology +12